28 results
8-K
EX-99.1
RVMD
Revolution Medicines Inc
26 Feb 24
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
4:04pm
wind-down and transition costs. At the closing, Dr. Sandra Horning joined the company’s board of directors. Wind-down of EQRx operations … compensation. Research and development expenses for the quarter ended December 31, 2023, included $13.1 million of expenses related to the wind-down of EQRx
8-K
EX-99.1
i43iyvq8c
6 Nov 23
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
4:05pm
DEFA14A
ug5sl
1 Nov 23
Additional proxy soliciting materials
7:15am
425
61f0vg58
1 Nov 23
Business combination disclosure
7:11am
8-K
EX-99.1
qqjrymiohofo o8moe6k
1 Nov 23
Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112
7:08am
8-K
9w4d2zj 1mjyb89
1 Nov 23
Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112
7:08am
425
kvw2agxm
23 Oct 23
Business combination disclosure
6:13am
DEFM14A
304bv3bkvx av29o2
29 Sep 23
Proxy related to merger
4:19pm
424B3
owqb ze7s1
29 Sep 23
Prospectus supplement
4:17pm
S-4/A
k7e wzvzgffgk4w95
27 Sep 23
Registration of securities issued in business combination transactions (amended)
5:25pm
S-4
ci97pbbp
13 Sep 23
Registration of securities issued in business combination transactions
5:20pm
425
8v2y kkxfii
1 Aug 23
Business combination disclosure
5:24pm
425
b61x 28oqjvdt8e164i
1 Aug 23
Business combination disclosure
5:22pm
425
u7hc2dcfqeaqj6lah87
1 Aug 23
Business combination disclosure
5:16pm
425
1rg8hh 7k
1 Aug 23
Business combination disclosure
5:13pm